Parenteral vitamin B12 therapy of hyperhomocysteinemia in end-stage renal disease

Clinical and Investigative Medicine

Volumn 27, Issue 1, 2004, Pages 10-13

  Hoffer, L John ^a,b   Elian, Kelly M ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; HYDROXOCOBALAMIN; METHYLMALONIC ACID; PYRIDOXINE; CYANOCOBALAMIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; TABLET FORMULATION; BLOOD; CHRONIC KIDNEY FAILURE; CYANOCOBALAMIN DEFICIENCY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PARENTERAL NUTRITION; TIME;

ADMINISTRATION, ORAL; AGED; FOLIC ACID; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; METHYLMALONIC ACID; MIDDLE AGED; PARENTERAL NUTRITION; TIME FACTORS; VITAMIN B 12; VITAMIN B 12 DEFICIENCY;

EID: 1842739563     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996;94:2743-8.
2. Clarke R, Lewington S, Landray M. Homocysteine, renal function, and risk of cardiovascular disease. Kidney Int 2003;63(Suppl 84):S131-S133.
3. Sunder-Plassmann G, Fodinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000;11:1106-16.
4. Tremblay R, Bonnardeaux A, Geadah D, Busque L, LeBrun M, Ouimet D, et al. Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int 2000;58:851-8.
5. 12 and high-dose folic acid in hemodialysis patients with hyperhomocyst(e)inemia. Kidney Int 2001;59:1103-9.
6. Bostom AG, Shemin D, Bagley P, Massy ZA, Zanabli A, Christopher K, et al. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation 2000;101:2829-32.
7. van Tellingen A, Grooteman MC, Bartels PM, van Limbeek J, van Guldener C, Ter Wee PM, et al. Long-term reduction of plasma homocysteine levels by superflux dialyzers in hemodialysis patients. Kidney Int 2001;59:342-7.
8. Elian KM, Hoffer LJ. Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease. Metabolism 2002;51:881-6.
9. Koyama K, Usami T, Takeuchi O, Morozumi K, Kimura G. Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in hæmodialysis patients receiving high-dose folic acid supplementation. Nephrol Dial Transplant 2002;17:916-22.
10. Hvas AM, Juul S, Gerdes LU, Nexo E. The marker of cobalamin deficiency, plasma methylmalonic acid, correlates to plasma creatinine. J Intern Med 2000;247:507-12.
11. 12 clearance. Intern Med 1993;32:194-6.
12. 12. Metabolism 2002;51:399-402.
13. 12. Biochem Biophys Res Commun 1999;259:436-42.
14. 12. J Biol Chem 2003;278:20778-84.
15. 12 and folate. Clin Chem 2000;46:1277-83.
16. Lindgren A. Elevated serum methylmalonic acid. How much comes from cobalamin deficiency and how much comes from the kidneys? Scand J Clin Lab Invest 2002;62:15-9.
17. Moelby L, Rasmussen K, Rasmussen HH. Serum methylmalonic acid in uræmia. Scand J Clin Lab Invest 1992;52:351-4.